Sugi Predict

Sugi Predict / Compounds / SCHEMBL3265383

SCHEMBL3265383

SCHEMBL3265383

O=C(Nc1ccc(C2CCC(c3ccc(NC(=O)[C@@H]4CCCN4)cc3)N2c2ccc(F)cc2)cc1)[C@@H]1CCCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.45
▸ PDGFRB P09619 2/20 0.45
▸ FLT3 P36888 2/20 0.45
▸ IKBKB O14920 1/20 0.45
▸ KIT P10721 1/20 0.45
▸ PDGFRA P16234 1/20 0.45
▸ FLT1 P17948 1/20 0.45
▸ RPS6KB1 P23443 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ TYK2 P29597 1/20 0.45
▸ FLT4 P35916 1/20 0.45
▸ KDR P35968 1/20 0.45
▸ JAK3 P52333 1/20 0.45
▸ MAP3K9 P80192 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ CIT O14578 1/20 0.45
▸ GAK O14976 1/20 0.45
▸ BUB1 O43683 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ PRKD3 O94806 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15887531 0.87 PFKFB3 (0.40) JAK2PDGFRBFLT3IKBKBKIT
SCHEMBL3266041 0.86 SCN3A (0.45) JAK2PDGFRBFLT3IKBKBKIT
SCHEMBL3047811 0.85 SCN3A (0.55) SCN3ASCN9APSMB8POLBSCN5A
Hydrochloric Acid SCHEMBL1981876 0.84 JAK2 (0.46) JAK2PDGFRBFLT3IKBKBKIT
Hydrochloric Acid SCHEMBL3782783 0.84 JAK2 (0.46) JAK2PDGFRBFLT3IKBKBKIT
SCHEMBL2756452 0.83 HDAC2 (0.47) FLT3ROCK2
SCHEMBL16381534 0.83 HDAC2 (0.47) FLT3ROCK2
SCHEMBL18913949 0.82 JAK2 (0.45) JAK2PDGFRBFLT3IKBKBKIT
SCHEMBL13708498 0.81 ULK1 (0.55) AAK1SCN3ASCN9APSMB8POLB
Hydrochloric Acid SCHEMBL15876518 0.80 SCN3A (0.38) JAK2PDGFRBFLT3IKBKBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 — — US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 — — US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 — — EP disclosed
US-9586978-B2 Anti-viral compounds ABBVIE INC. (US) 2017-03-07 — — US disclosed
EP-2692346-B1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative ABBVIE BAHAMAS LTD (BS) 2015-12-02 — — EP disclosed
US-20150218194-A1 Anti-Viral Compounds ABBVIE INC. (US) 2015-08-06 — — US disclosed
US-20150087618-A1 Anti-Viral Compounds ABBVIE INC. (US) 2015-03-26 — — US disclosed
US-8937150-B2 Anti-viral compounds ABBVIE INC. (US) 2015-01-20 — — US disclosed
US-8921514-B2 Anti-viral compounds ABBVIE INC. (US) 2014-12-30 — — US disclosed
US-20140315792-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES 2014-10-23 — — US disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 — — US disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 — — US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20140315792-A1 ANTI-VIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20150087618-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20150218194-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS JAK2 979/4885PDGFRB 2060/4885FLT3 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.